Nearly a decade after losing a bidding war for device maker Guidant to Boston Scientific Corp, Johnson & Johnson finally has a chance for payback at a multibillion-dollar trial set to begin on Thursday.
Medical
AbbVie adds children's AIDS drugs to shared patent pool
U.S. drugmaker AbbVie has added two HIV medicines for children to a shared patent pool in an initiative that should speed the development of cheap new pediatric formulations for use in poor countries.
China drafts policy on emergency Ebola diagnosis, approves products
China has drafted a policy on the emergency use of diagnostic products for the Ebola virus disease and clinical trials, the country's drug regulator said on Friday, as the number of people affected globally by the epidemic nears 16,000.
Medtronic wins conditional EU approval for $43 billion Covidien buy
U.S. medical device maker Medtronic (MDT.N) gained European Union regulatory approval on Friday for its $43 billion takeover of Covidien Plc (COV.N) after agreeing to sell its Irish rival's drug-coated balloon catheter business.
First gene therapy drug sets million-euro price record
The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.
Latest News
Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014.
The chief executive of Quest Diagnostics Inc (DGX.N) said his company will stick to its core business of diagnostic testing and is not interested in acquiring a contract research organization (CRO), despite such a planned move by rival diagnostics firm LabCorp (LH.N).
AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.
Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday.
Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).
Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) on Monday said in a letter to Allergan Inc's (AGN.N) board of directors that it was prepared to raise its offer to at least $200 per share but stopped short of doing so.
Japan's Fujifilm Holdings Corp said on Monday it would buy 49 percent of Texas-based Kalon Biotherapeutics LLC, which has expertise in manufacturing vaccines used against pandemic influenza, Ebola and other public-health threats.
Drugmakers Abbott Laboratories (ABT.N) and Mylan Inc (MYL.O) on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.
